Aptevo Therapeutics Files S-1 for Securities Offering
Ticker: APVO · Form: S-1 · Filed: May 13, 2025 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | S-1 |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: s-1, securities-offering, pharmaceuticals
Related Tickers: APVO
TL;DR
APVO filed an S-1, looks like they're raising cash.
AI Summary
Aptevo Therapeutics Inc. filed an S-1 registration statement with the SEC on May 13, 2025, to register an unspecified number of securities. The company, headquartered in Seattle, WA, is in the pharmaceutical preparations industry and is incorporated in Delaware. Marvin L. White serves as President and CEO, and SoYoung Kwon is the Senior Vice President and General Counsel.
Why It Matters
This S-1 filing indicates Aptevo Therapeutics is preparing to raise capital through a securities offering, which could fund its drug development pipeline or other corporate initiatives.
Risk Assessment
Risk Level: medium — As an S-1 filing, it signifies a potential offering of new securities, which can dilute existing shareholders and introduce market uncertainty.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry)
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- May 13, 2025 (date) — Filing Date
- 2401 4th Avenue, Suite 1050 Seattle, WA 98121 (location) — Principal Executive Offices
- Marvin L. White (person) — President and Chief Executive Officer
- SoYoung Kwon (person) — Senior Vice President and General Counsel
- 333-287244 (registration_number) — SEC File Number
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement filed with the SEC to register securities for a potential public offering.
When was this S-1 filing submitted?
The S-1 filing was submitted on May 13, 2025.
What is Aptevo Therapeutics Inc.'s primary business?
Aptevo Therapeutics Inc. is in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
Who are the key executives mentioned in the filing?
Marvin L. White is listed as President and Chief Executive Officer, and SoYoung Kwon is listed as Senior Vice President and General Counsel.
Where is Aptevo Therapeutics Inc. headquartered?
The company's principal executive offices are located at 2401 4th Avenue, Suite 1050, Seattle, WA 98121.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on May 13, 2025 by Marvin L. White regarding Aptevo Therapeutics Inc. (APVO).